Table 2.
Echocardiographic parameters and prognostic information of included studies.
| Study | Mean AV area (cm2) | Mean AV pressure gradient (mmHg) | AVmax (m/s) | LVEFpre | LVEFpos |
LV/RV LSpre |
LV/RV LSpos |
Cut-off of LS |
HR/OR (95%CI) |
Index | Ventricular | Outcome |
Event rate |
Hospitalization rate (%) |
Mean or median of follow-up | Equipment or platform |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wani et al. (16) | 0.77 | 41.8 | NR | 55 | 57 | 13.9 ± 4.3 | 14.8 ± 4.3 | NA | 0.97 (0.91–1.03) | OR | LV | MACE | 35% | 30 | 1 year | GE Vivid E9, E95 |
| Shimoni et al. (17) | 0.71 | 45.9 | NR | 53.7 | 53.7 | 17 ± 5 | 18.4 ± 4.9 | NA | 1.130 (1.008–1.127) | HR | LV | ACM | 20% | 42 | 1,150 days | GE Echo PAC 202 |
| Ferreira et al. (18) | 0.6 | 57 | NR | 56.7 | NR | 13.0 ± 3.8 | NR | NA | 1.00 (0.88–1.14) | HR | LV | ACM | 18% | NR | 13.4 months | GE Vivid 9, Vivid E95 |
| 14.8 | 2.08 (0.59–7.31) | |||||||||||||||
| Omran et al. (19) | 0.72 | 47 | NR | 51.4 | NR | 20.0 ± 7.6 | 19.8 ± 7.8 | NA | 1.05 (1.01–1.10) | HR | RV | ACM | 17% | NR | 929 days | NR |
| Koschutnik et al. (20) | NR | NR | NR | 57 | NR | 22.8 ± 6.9 | NR | NA | 1.44 (1.03–2.01) | OR | RV | MACE | 28% | 5 | 13.7 months | GE Vivid E9,Vivid 7 |
| 20 | 1.74 (0.91–3.32) | |||||||||||||||
| Vizzardi et al. (21) | NR | 51 | NR | 51 | NR | 17.6 ± 4.8 | NR | NA | 1.14 (1.072–1.213) | HR | RV | ACM | 82% | NR | 8.5 years | GE, Philips, Siemens |
| Medvedofsky et al. (12) | 0.44 | 49 | NR | 53 | NR | 24.6 ± 6.3 | 26.9 ± 5.8 | NA | 1.04 (1.01–1.07) | HR | RV | ACM | 24% | NR | 1 year | Philips iE33; EPIQ 7C |
| Dahl Pedersen et al. (22) | 0.68 | 41 | NR | 50.9 | NR | 12.9 ± 4 | NR | 12.9 | 1.52 (0.96–2.40) | HR | LV | ACM | 15% | NR | 743 days | GE Vivid E 90 |
| Fukui et al. (11) | NR | NR | NR | 62.2 | NR | 18.2 ± 4.1 | NR | 16 | 1.36 (0.93–1.99) | HR | LV | ACM | 37% | NR | 31 months | GE Vivid E95, |
| Suzuki- et al. (23) | 0.65 | 50 | 4.5 | 62 | 64 | 15 ± 4.4 | 16 ± 4.3 | NA | 1.23 (1.05–1.45) | OR | LV | MACE | 10% | NR | 591 days | NR |
| Sato et al. (28) | NR | 47 | 4.37 | 50 | 53 | 12.0 ± 3.7 | 13.0 ± 3.6 | NA | 1.05 (1.002–1.11) | HR | LV | ACM | 56% | NR | 1,345 days | Xcelera, Philips |
| Kobayashi et al. (15) | 0.63 | 49.6 | NR | 54 | NR | 13.0 ± 3.3 | NR | 15 | 1.35 (0.24–7.49) | HR | LV | ACM | 19% | NR | 376 days | GE Vivid E9, E95 |
AV, aortic valve; LVEF, left ventricular ejection fraction; LS, longitudinal strain; HR, hazard ratio; OR, odds ratio; LV, left ventricular; RV, right ventricular; ACM, all-cause mortality; MACE, major adverse cardiovascular events; NR, Not reported; NA, not applicable.